Navigation Links
DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent
Date:3/2/2009

CLEVELAND, March 2 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the return of Chris Wilke as Vice President of Research and Development. In his role as DATATRAK's Vice President of R&D, Mr. Wilke will report directly to Raymond J. Merk, DATATRAK's Chief Financial Officer and Chief Operating Officer, and be integrally involved in the development of the DATATRAK eClinical platform.

Mr. Merk commented, "We are delighted that Chris has returned to DATATRAK. His track record of success at the Company coupled with the strong partnership he has forged with our R&D team will serve DATATRAK well as we drive our business forward."

The Company also announced that the U.S. Patent and Trademark Office has approved the issuance of Patent No. 7,464,087 (Method and System For Unifying Data) which covers methods for unifying data from a plurality of heterogeneous databases, each having business-context related data and a data access mechanism.

"The cornerstone of DATATRAK's business is providing our customers with the tools and technologies necessary to unify their clinical trial processes, and this patent is a clear example of this commitment," noted Mr. Wilke. "Whether it is randomization, coding, data entry, data cleaning, reporting or other need, we are continually improving our customer's ability to manage their own enterprise while providing end users the functionality and ease of use they desire."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the Nasdaq Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK International Management To Host Conference Call on November 8, 2007 To Discuss Third Quarter and Nine Month Operating Results for 2007
2. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
3. DATATRAK International Launches Innovative, Interactive Educational Webcast Series
4. DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference
5. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
6. DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007
7. DATATRAK International Reports Fourth Quarter and Full Year Results for 2007
8. DATATRAK Announces Restructured Senior Management Team
9. Ease-of-Use and Intuitive Nature of the DATATRAK eClinical(TM) Platform Allows for Further Operational Efficiencies
10. DATATRAK International, Inc. Receives Notice From Nasdaq
11. DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... California ... in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Compensation Research Institute (WCRI) . , According to the study, medical payments per claim ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...
(Date:12/7/2016)... ... , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than ... multi-function, sealed, LED luminaire that meets the needs of everyone in the patient room ... , A 2’ x 4’ model features four modes: reading, ambient, standard and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... it has acquired Presence Technology, S.L. (“Presence”) for a purchase price of ... adjustments and other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... PHOENIX , Dec. 8, 2016 A ... by the National Institutes of Health (NIH) to ... State University.  The grant will seek ... NeuroEM,s head device, which utilizes electromagnetic waves to treat ... of this novel technology to possibly treat other neurologic ...
(Date:12/8/2016)... Ariz., Dec. 8, 2016  Economic growth in the ... purchasing and supply management executives in their December 2016 ... the economic recovery that began in mid-2009, as indicated ... Business ® . The manufacturing sector is optimistic ... in 16 manufacturing industries, and the non-manufacturing sector indicates ...
(Date:12/8/2016)... Dec. 8, 2016  Hanson Research, an innovative ... testing and diffusion testing instruments for the pharmaceutical ... Teledyne Instruments, Inc. ("Teledyne"). The move is designed ... precision testing instruments, as well as expand resources ... new products and services. Logo - ...
Breaking Medicine Technology: